Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

Ningning Liu, Xiaofen Li, Hongbiao Huang, Chong Zhao, Siyan Liao, Changshan Yang, Shouting Liu, Wenbin Song, Xiaoyu Lu, Xiaoying Lan, Xin Chen, Songgang Yi, Li Xu, Lili Jiang, Canguo Zhao, Xiaoxian Dong, Ping Zhou, Shujue Li, Shunqing Wang, Xianping ShiPing Q. Dou, Xuejun Wang, Jinbao Liu

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.

Original languageEnglish (US)
Pages (from-to)5453-5471
Number of pages19
JournalOncotarget
Volume5
Issue number14
DOIs
StatePublished - 2014

Fingerprint

Auranofin
Antirheumatic Agents
Proteasome Endopeptidase Complex
Growth
Neoplasms
Gold Compounds
Phase II Clinical Trials
Rheumatic Fever
United States Food and Drug Administration
Deubiquitinating Enzymes
Acute Myeloid Leukemia
Metals

Keywords

  • Auranofin
  • Cancer
  • Deubiquitinase
  • Proteasome

ASJC Scopus subject areas

  • Oncology

Cite this

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. / Liu, Ningning; Li, Xiaofen; Huang, Hongbiao; Zhao, Chong; Liao, Siyan; Yang, Changshan; Liu, Shouting; Song, Wenbin; Lu, Xiaoyu; Lan, Xiaoying; Chen, Xin; Yi, Songgang; Xu, Li; Jiang, Lili; Zhao, Canguo; Dong, Xiaoxian; Zhou, Ping; Li, Shujue; Wang, Shunqing; Shi, Xianping; Dou, Ping Q.; Wang, Xuejun; Liu, Jinbao.

In: Oncotarget, Vol. 5, No. 14, 2014, p. 5453-5471.

Research output: Contribution to journalArticle

Liu, N, Li, X, Huang, H, Zhao, C, Liao, S, Yang, C, Liu, S, Song, W, Lu, X, Lan, X, Chen, X, Yi, S, Xu, L, Jiang, L, Zhao, C, Dong, X, Zhou, P, Li, S, Wang, S, Shi, X, Dou, PQ, Wang, X & Liu, J 2014, 'Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth', Oncotarget, vol. 5, no. 14, pp. 5453-5471. https://doi.org/10.18632/oncotarget.2113
Liu, Ningning ; Li, Xiaofen ; Huang, Hongbiao ; Zhao, Chong ; Liao, Siyan ; Yang, Changshan ; Liu, Shouting ; Song, Wenbin ; Lu, Xiaoyu ; Lan, Xiaoying ; Chen, Xin ; Yi, Songgang ; Xu, Li ; Jiang, Lili ; Zhao, Canguo ; Dong, Xiaoxian ; Zhou, Ping ; Li, Shujue ; Wang, Shunqing ; Shi, Xianping ; Dou, Ping Q. ; Wang, Xuejun ; Liu, Jinbao. / Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. In: Oncotarget. 2014 ; Vol. 5, No. 14. pp. 5453-5471.
@article{ace1ee968a99441cbe2a730a38fb06e1,
title = "Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth",
abstract = "Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.",
keywords = "Auranofin, Cancer, Deubiquitinase, Proteasome",
author = "Ningning Liu and Xiaofen Li and Hongbiao Huang and Chong Zhao and Siyan Liao and Changshan Yang and Shouting Liu and Wenbin Song and Xiaoyu Lu and Xiaoying Lan and Xin Chen and Songgang Yi and Li Xu and Lili Jiang and Canguo Zhao and Xiaoxian Dong and Ping Zhou and Shujue Li and Shunqing Wang and Xianping Shi and Dou, {Ping Q.} and Xuejun Wang and Jinbao Liu",
year = "2014",
doi = "10.18632/oncotarget.2113",
language = "English (US)",
volume = "5",
pages = "5453--5471",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "14",

}

TY - JOUR

T1 - Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

AU - Liu, Ningning

AU - Li, Xiaofen

AU - Huang, Hongbiao

AU - Zhao, Chong

AU - Liao, Siyan

AU - Yang, Changshan

AU - Liu, Shouting

AU - Song, Wenbin

AU - Lu, Xiaoyu

AU - Lan, Xiaoying

AU - Chen, Xin

AU - Yi, Songgang

AU - Xu, Li

AU - Jiang, Lili

AU - Zhao, Canguo

AU - Dong, Xiaoxian

AU - Zhou, Ping

AU - Li, Shujue

AU - Wang, Shunqing

AU - Shi, Xianping

AU - Dou, Ping Q.

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2014

Y1 - 2014

N2 - Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.

AB - Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.

KW - Auranofin

KW - Cancer

KW - Deubiquitinase

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=84906249813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906249813&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2113

DO - 10.18632/oncotarget.2113

M3 - Article

C2 - 24977961

AN - SCOPUS:84906249813

VL - 5

SP - 5453

EP - 5471

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -